OncoMatch/Clinical Trials/NCT06381817
Haplo-cord HCT vs. Haplo-HCT for T-ALL Patients
Is NCT06381817 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Haplo-cord HCT and Haplo-HCT for acute t cell lymphoblastic leukemia.
Treatment: Haplo-cord HCT · Haplo-HCT — The goal of this clinical trial is to learn if haploidentical hematopoietic cell transplantation combined with an unrelated cord blood unit (haplo-cord HCT) works to treat acute T cell lymphoblastic leukemia (T-ALL). It will also learn about the safety of the transplantation. The main questions it aims to answer are: Dose co-infusion of cord blood in haploidentical hematopoietic cell transplantation (haplo-HCT) lower the rate of relapse? What medical problems do participants have when having haplo-cord HCT? Researchers will compare haplo-cord HCT to haplo-HCT to see if haplo-cord HCT works to treat T-ALL. Participants will be infused an unrelated cord blood unit at the same day of haploidentical graft infusion.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Cannot have received: autologous hematopoietic cell transplantation
Cannot have received: allogeneic hematopoietic cell transplantation
Cannot have received: car-t cell therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify